

First-in-human trial exploring safety, antitumor activity,  
recombinant pan-HER antibody mixture, in advanced e

Investigational New Drugs

, 1

DOI: 10.1007/s10637-022-01217-7

Citation Report

#	ARTICLE	IF	CITATIONS
1	It is Never Too Late for a Cocktail - Development and Analytical Characterization of Fixed-dose Antibody Combinations. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2149-2157.	1.6	2
2	Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. <i>Cancers</i> , 2022, 14, 4543.	1.7	9
3	HER3 in cancer: from the bench to the bedside. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	20
4	HER3 Alterations in Cancer and Potential Clinical Implications. <i>Cancers</i> , 2022, 14, 6174.	1.7	4